Effects of a novel ascorbate-based protocol on infarct size and ventricle function in acute myocardial infarction patients undergoing percutaneous coronary angioplasty

Cristóbal Ramos, Roberto Brito, Jaime González-Montero, Nicolás Valls, Juan G. Gormaz, Juan C. Prieto, Rubén Aguayo, Ángel Puentes, Viviana Noriega, Gonzalo Pereira, Tamara Palavecino, Ramón Rodrigo

Resultado de la investigación: Article

1 Cita (Scopus)

Resumen

Introduction: This study was designed to test the hypothesis that high-dose ascorbate prior to reperfusion followed by low chronic oral doses ameliorate myocardial reperfusion injury (MRI) in acute myocardial infarction patients subjected to primary percutaneous coronary angioplasty (PCA). Material and methods: A randomized double-blind placebo-controlled and multicenter clinical trial was performed on acute myocardial infarction (AMI) patients who underwent PCA. Sodium ascorbate (320 mmol/l, n = 53) or placebo (n = 46) was infused 30 min prior to PCA. Blood samples were drawn at enrolment (M1), after balloon deflation (M2), 6-8 h after M2 (M3) and at discharge (M4). Total antioxidant capacity of plasma (ferric reducing ability of plasma - FRAP), erythrocyte reduced glutathione (GSH) and plasma ascorbate levels were determined in blood samples. Cardiac magnetic resonance (CMR) was performed at 7-15 days and 2-3 months following PCA. Ninety- nine patients were enrolled. In 67 patients, the first CMR was performed, and 40 patients completed follow-up. Results: The ascorbate group showed significantly higher ascorbate and FRAP levels and a decrease in the GSH levels at M2 and M3 (p < 0.05). There were no significant differences in the infarct size, indexed end-systolic volume and ejection fraction at both CMRs. There was a significant amelioration in the decreased ejection fraction between the first and second CMR in the ascorbate group (p < 0.05). Conclusions: Ascorbate given prior to reperfusion did not show a significant difference in infarct size or ejection fraction. However, it improved the change in ejection fraction determined between 7-15 days and 2-3 months. This result hints at a possible functional effect of ascorbate to ameliorate MRI.

Idioma originalEnglish
Páginas (desde-hasta)558-567
Número de páginas10
PublicaciónArchives of Medical Science
Volumen13
N.º3
DOI
EstadoPublished - 2017

Huella dactilar

Angioplasty
Myocardial Infarction
Myocardial Reperfusion Injury
Magnetic Resonance Spectroscopy
Reperfusion
Placebos
Controlled Clinical Trials
Ascorbic Acid
Multicenter Studies
Glutathione
Antioxidants
Erythrocytes

ASJC Scopus subject areas

  • Medicine(all)

Citar esto

Ramos, Cristóbal ; Brito, Roberto ; González-Montero, Jaime ; Valls, Nicolás ; Gormaz, Juan G. ; Prieto, Juan C. ; Aguayo, Rubén ; Puentes, Ángel ; Noriega, Viviana ; Pereira, Gonzalo ; Palavecino, Tamara ; Rodrigo, Ramón. / Effects of a novel ascorbate-based protocol on infarct size and ventricle function in acute myocardial infarction patients undergoing percutaneous coronary angioplasty. En: Archives of Medical Science. 2017 ; Vol. 13, N.º 3. pp. 558-567.
@article{a2eb9c9e226249d1ad8380bb0996d52c,
title = "Effects of a novel ascorbate-based protocol on infarct size and ventricle function in acute myocardial infarction patients undergoing percutaneous coronary angioplasty",
abstract = "Introduction: This study was designed to test the hypothesis that high-dose ascorbate prior to reperfusion followed by low chronic oral doses ameliorate myocardial reperfusion injury (MRI) in acute myocardial infarction patients subjected to primary percutaneous coronary angioplasty (PCA). Material and methods: A randomized double-blind placebo-controlled and multicenter clinical trial was performed on acute myocardial infarction (AMI) patients who underwent PCA. Sodium ascorbate (320 mmol/l, n = 53) or placebo (n = 46) was infused 30 min prior to PCA. Blood samples were drawn at enrolment (M1), after balloon deflation (M2), 6-8 h after M2 (M3) and at discharge (M4). Total antioxidant capacity of plasma (ferric reducing ability of plasma - FRAP), erythrocyte reduced glutathione (GSH) and plasma ascorbate levels were determined in blood samples. Cardiac magnetic resonance (CMR) was performed at 7-15 days and 2-3 months following PCA. Ninety- nine patients were enrolled. In 67 patients, the first CMR was performed, and 40 patients completed follow-up. Results: The ascorbate group showed significantly higher ascorbate and FRAP levels and a decrease in the GSH levels at M2 and M3 (p < 0.05). There were no significant differences in the infarct size, indexed end-systolic volume and ejection fraction at both CMRs. There was a significant amelioration in the decreased ejection fraction between the first and second CMR in the ascorbate group (p < 0.05). Conclusions: Ascorbate given prior to reperfusion did not show a significant difference in infarct size or ejection fraction. However, it improved the change in ejection fraction determined between 7-15 days and 2-3 months. This result hints at a possible functional effect of ascorbate to ameliorate MRI.",
keywords = "Ascorbate, Myocardial reperfusion injury, Oxidative stress",
author = "Crist{\'o}bal Ramos and Roberto Brito and Jaime Gonz{\'a}lez-Montero and Nicol{\'a}s Valls and Gormaz, {Juan G.} and Prieto, {Juan C.} and Rub{\'e}n Aguayo and {\'A}ngel Puentes and Viviana Noriega and Gonzalo Pereira and Tamara Palavecino and Ram{\'o}n Rodrigo",
year = "2017",
doi = "10.5114/aoms.2016.59713",
language = "English",
volume = "13",
pages = "558--567",
journal = "Archives of Medical Science",
issn = "1734-1922",
publisher = "Termedia Publishing House Ltd.",
number = "3",

}

Ramos, C, Brito, R, González-Montero, J, Valls, N, Gormaz, JG, Prieto, JC, Aguayo, R, Puentes, Á, Noriega, V, Pereira, G, Palavecino, T & Rodrigo, R 2017, 'Effects of a novel ascorbate-based protocol on infarct size and ventricle function in acute myocardial infarction patients undergoing percutaneous coronary angioplasty', Archives of Medical Science, vol. 13, n.º 3, pp. 558-567. https://doi.org/10.5114/aoms.2016.59713

Effects of a novel ascorbate-based protocol on infarct size and ventricle function in acute myocardial infarction patients undergoing percutaneous coronary angioplasty. / Ramos, Cristóbal; Brito, Roberto; González-Montero, Jaime; Valls, Nicolás; Gormaz, Juan G.; Prieto, Juan C.; Aguayo, Rubén; Puentes, Ángel; Noriega, Viviana; Pereira, Gonzalo; Palavecino, Tamara; Rodrigo, Ramón.

En: Archives of Medical Science, Vol. 13, N.º 3, 2017, p. 558-567.

Resultado de la investigación: Article

TY - JOUR

T1 - Effects of a novel ascorbate-based protocol on infarct size and ventricle function in acute myocardial infarction patients undergoing percutaneous coronary angioplasty

AU - Ramos, Cristóbal

AU - Brito, Roberto

AU - González-Montero, Jaime

AU - Valls, Nicolás

AU - Gormaz, Juan G.

AU - Prieto, Juan C.

AU - Aguayo, Rubén

AU - Puentes, Ángel

AU - Noriega, Viviana

AU - Pereira, Gonzalo

AU - Palavecino, Tamara

AU - Rodrigo, Ramón

PY - 2017

Y1 - 2017

N2 - Introduction: This study was designed to test the hypothesis that high-dose ascorbate prior to reperfusion followed by low chronic oral doses ameliorate myocardial reperfusion injury (MRI) in acute myocardial infarction patients subjected to primary percutaneous coronary angioplasty (PCA). Material and methods: A randomized double-blind placebo-controlled and multicenter clinical trial was performed on acute myocardial infarction (AMI) patients who underwent PCA. Sodium ascorbate (320 mmol/l, n = 53) or placebo (n = 46) was infused 30 min prior to PCA. Blood samples were drawn at enrolment (M1), after balloon deflation (M2), 6-8 h after M2 (M3) and at discharge (M4). Total antioxidant capacity of plasma (ferric reducing ability of plasma - FRAP), erythrocyte reduced glutathione (GSH) and plasma ascorbate levels were determined in blood samples. Cardiac magnetic resonance (CMR) was performed at 7-15 days and 2-3 months following PCA. Ninety- nine patients were enrolled. In 67 patients, the first CMR was performed, and 40 patients completed follow-up. Results: The ascorbate group showed significantly higher ascorbate and FRAP levels and a decrease in the GSH levels at M2 and M3 (p < 0.05). There were no significant differences in the infarct size, indexed end-systolic volume and ejection fraction at both CMRs. There was a significant amelioration in the decreased ejection fraction between the first and second CMR in the ascorbate group (p < 0.05). Conclusions: Ascorbate given prior to reperfusion did not show a significant difference in infarct size or ejection fraction. However, it improved the change in ejection fraction determined between 7-15 days and 2-3 months. This result hints at a possible functional effect of ascorbate to ameliorate MRI.

AB - Introduction: This study was designed to test the hypothesis that high-dose ascorbate prior to reperfusion followed by low chronic oral doses ameliorate myocardial reperfusion injury (MRI) in acute myocardial infarction patients subjected to primary percutaneous coronary angioplasty (PCA). Material and methods: A randomized double-blind placebo-controlled and multicenter clinical trial was performed on acute myocardial infarction (AMI) patients who underwent PCA. Sodium ascorbate (320 mmol/l, n = 53) or placebo (n = 46) was infused 30 min prior to PCA. Blood samples were drawn at enrolment (M1), after balloon deflation (M2), 6-8 h after M2 (M3) and at discharge (M4). Total antioxidant capacity of plasma (ferric reducing ability of plasma - FRAP), erythrocyte reduced glutathione (GSH) and plasma ascorbate levels were determined in blood samples. Cardiac magnetic resonance (CMR) was performed at 7-15 days and 2-3 months following PCA. Ninety- nine patients were enrolled. In 67 patients, the first CMR was performed, and 40 patients completed follow-up. Results: The ascorbate group showed significantly higher ascorbate and FRAP levels and a decrease in the GSH levels at M2 and M3 (p < 0.05). There were no significant differences in the infarct size, indexed end-systolic volume and ejection fraction at both CMRs. There was a significant amelioration in the decreased ejection fraction between the first and second CMR in the ascorbate group (p < 0.05). Conclusions: Ascorbate given prior to reperfusion did not show a significant difference in infarct size or ejection fraction. However, it improved the change in ejection fraction determined between 7-15 days and 2-3 months. This result hints at a possible functional effect of ascorbate to ameliorate MRI.

KW - Ascorbate

KW - Myocardial reperfusion injury

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85019558171&partnerID=8YFLogxK

U2 - 10.5114/aoms.2016.59713

DO - 10.5114/aoms.2016.59713

M3 - Article

AN - SCOPUS:85019558171

VL - 13

SP - 558

EP - 567

JO - Archives of Medical Science

JF - Archives of Medical Science

SN - 1734-1922

IS - 3

ER -